Govt allows Ramdev to market Patanjali's Coronil as immunity booster; not authorised for Covid therapy

Aditi Tandon
Tribune News Service
New Delhi, July 1

After banning the advertisement for Patanjali Trust’s new drug, Coronil for “COVID-19 treatment”, the government on Wednesday said, the firm could market the medicine as an immunity booster, and not as a COVID-19 drug.

In a letter to Uttarakhand Licensing Authority and Ramdev’s Patanjali Trust, the Ministry of Ayush said that it examined the matter and found that Coronil was registered with a state licensing authority as an immunity booster. The two other drugs, in the so-called COVID-19 package, which Patanjali announced was registered as Ayurvedic drugs for ‘Kasa and Savasa’.

Earlier this June, the Trust had applied for the licences with the state authority.

The Ministry letter to Ramdev reads: “The proposed three drugs—Divya Coronil tablet, Divya Shwashari Vati 540MG and Divya Shwashari Vati 350 MG should be marketed as per the scope of the licence issued by Uttarakhand Licensing Authority, Ayurvedic and Unani Services. On the package and label of these drugs no claim of cure of COVID-19 should be mentioned.”

The Ministry added that Patanjali Trust had initiated clinical trials for COVID-19 therapy, as per the government guideline, and the Trust could continue those trials as per the required procedure.